NYSE: MRK
Merck & Co Inc Earnings & Revenue

MRK past earnings growth

How has MRK's earnings growth performed historically?
Company
14.72%
Industry
10.68%
Market
82.89%
MRK's earnings have grown slower (3.78% per year) than the US Drug Manufacturers - General industry average (8.89%)
Performance
MRK's earnings have grown slower (3.78% per year) than the US market average (77.34%)
Performance
MRK's earnings growth is accelerating - its growth over the last year (14.72%) is above its 5-year compound annual rate (3.78%)
Performance

MRK past revenue growth

How has MRK's revenue growth performed historically?
Company
6.37%
Industry
6.62%
Market
16.55%
MRK's revenue has grown slower (3.23% per year) than the US Drug Manufacturers - General industry average (4.07%)
Performance
MRK's revenue has grown slower (3.23% per year) than the US market average (15.67%)
Performance
MRK's revenue growth is accelerating - its growth over the last year (6.37%) is above its 5-year compound annual rate (3.23%)
Performance

MRK earnings and revenue history

Current Revenue
$47.2B
Current Earnings
$10.5B
Current Profit Margin
22.20%
MRK's has not demonstrated consistent long-term earnings growth over the past 10 years (-10.22%)
Performance

MRK Return on equity

Current Company
39.30%
Current Industry
10.90%
Current Market
-36.30%
MRK's Return on Equity (39.30%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

MRK Return on assets

Current Company
12.20%
Current Industry
8.50%
Current Market
6.20%
MRK is generating higher Return on Assets (12.20%) than the US Drug Manufacturers - General industry average (8.27%)
Performance

MRK Return on capital employed

Current Company
18.23%
Current Industry
12.80%
MRK has gotten more efficient at generating Return on Capital (18.23%) compared to 3 years ago (8.04%)
Performance

MRK earnings dates

Next earnings date
Oct 27, 2020

Merck & Earnings & Revenue FAQ

On Apr 28, 2020, Merck & (NYSE: MRK) reported Q1 2020 earnings per share (EPS) of $1.27, up 12.39% year over year. Total Merck & earnings for the quarter were $3.22 billion. In the same quarter last year, Merck &'s earnings per share (EPS) was $1.13.
On Apr 28, 2020, Merck & (NYSE: MRK) reported Q1 2020 revenue of $12.06 billion up 11.47% year over year. In the same quarter last year, Merck &'s revenue was $10.82 billion.
As of Q4 2020, Merck &'s earnings has grown 14.72% year over year. This is 4.04 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 10.68%. Merck &'s earnings in the past year totalled $10.48 billion.
As of Q4 2020, Merck &'s revenue has grown 6.37% year over year. This is 0.25 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 6.62%. Merck &'s revenue in the past year totalled $47.19 billion.
Merck &'s earnings date is Oct 27, 2020. Add MRK to your watchlist to be reminded of MRK's next earnings announcement.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics